Zolmitryptan (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zolmitryptan" in Polish language version.

Last modified: 14:52:00, 26 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank Polish rank

1414nih.gov

5^th place

7^th place

55doi.org

2^nd place

5^th place

22mp.pl

low place

285^th place

11drugbank.ca

5,595^th place

359^th place

11sigmaaldrich.com

774^th place

132^nd place

11scbt.com

low place

4,755^th place

11ama-assn.org

4,430^th place

low place

11arsxxi.com

low place

11aafp.org

2,559^th place

3,830^th place

aafp.org (Global: 2,559^th place; Polish: 3,830^th place)

Logemann CD., Rankin LM. Newer intranasal migraine medications. „American family physician”. 1 (61), s. 180–186, 2000. PMID: 10643958.

ama-assn.org (Global: 4,430^th place; Polish: low place)

archneur.ama-assn.org

Tepper SJ., Rapoport AM., Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. „Archives of neurology”. 7 (59), s. 1084–1088, 2002. PMID: 12117355.

arsxxi.com (Global: low place; Polish: low place)

Pascual J., Navarro A., Caminero AB., Jurado C. Experience with intranasal zolmitriptan in cluster headache. „Neurología (Barcelona, Spain)”. 3 (21), s. 131–134, 2006. PMID: 16575626.

doi.org (Global: 2^nd place; Polish: 5^th place)

Kayser V., Aubel B., Hamon M., Bourgoin S. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. „British journal of pharmacology”. 8 (137), s. 1287–1297, 2002. DOI: 10.1038/sj.bjp.0704979. PMID: 12466238.
Jähnichen S., Radtke OA., Pertz HH. Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. „Naunyn-Schmiedeberg’s archives of pharmacology”. 1 (370), s. 54–63, 2004. DOI: 10.1007/s00210-004-0941-6. PMID: 15185063.
Edvinsson L. CGRP-receptor antagonism in migraine treatment. „Lancet”. 9656 (372), s. 2089–2090, 2008. DOI: 10.1016/S0140-6736(08)61710-9. PMID: 19036426.
Loder E., Freitag FG., Adelman J., Pearlmand S., Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. „Current medical research and opinion”. 3 (21), s. 381–389, 2005. DOI: 10.1185/030079905X28926. PMID: 15811207.
Cittadini E., May A., Straube A., Evers S., Bussone G., Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. „Archives of neurology”. 11 (63), s. 1537–1542, 2006. DOI: 10.1001/archneur.63.11.nct60002. PMID: 16966497.

drugbank.ca (Global: 5,595^th place; Polish: 359^th place)

go.drugbank.ca

Zolmitriptan, [w:] DrugBank [online], University of Alberta, DB00315 (ang.).

mp.pl (Global: low place; Polish: 285^th place)

Zolmiles tabletki ulegające rozpadowi w jamie ustnej – działanie, dawkowanie, cena, refundacja | Medycyna Praktyczna [online], www.mp.pl [dostęp 2022-06-10] .
Zolmitriptan STADA tabletki – działanie, dawkowanie, cena, refundacja | Medycyna Praktyczna [online], www.mp.pl [dostęp 2022-06-10] .

nih.gov (Global: 5^th place; Polish: 7^th place)

ncbi.nlm.nih.gov

Kayser V., Aubel B., Hamon M., Bourgoin S. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. „British journal of pharmacology”. 8 (137), s. 1287–1297, 2002. DOI: 10.1038/sj.bjp.0704979. PMID: 12466238.
Tepper SJ., Rapoport AM., Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. „Archives of neurology”. 7 (59), s. 1084–1088, 2002. PMID: 12117355.
Jähnichen S., Radtke OA., Pertz HH. Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. „Naunyn-Schmiedeberg’s archives of pharmacology”. 1 (370), s. 54–63, 2004. DOI: 10.1007/s00210-004-0941-6. PMID: 15185063.
Edvinsson L. CGRP-receptor antagonism in migraine treatment. „Lancet”. 9656 (372), s. 2089–2090, 2008. DOI: 10.1016/S0140-6736(08)61710-9. PMID: 19036426.
Loder E., Freitag FG., Adelman J., Pearlmand S., Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. „Current medical research and opinion”. 3 (21), s. 381–389, 2005. DOI: 10.1185/030079905X28926. PMID: 15811207.
Seaber E., On N., Dixon RM., Gibbens M., Leavens WJ., Liptrot J., Chittick G., Posner J., Rolan PE., Pack RW. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). „British journal of clinical pharmacology”. 6 (43), s. 579–587, 1997. PMID: 9205817.
Tuchman MM., Hee A., Emeribe U., Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. „CNS drugs”. 10 (22), s. 877–886, 2008. PMID: 18788838.
Ficzere A., Csiba L. Treatment of migraine in patients with hypertension and ischemic heart disease. „Ideggyógyászati szemle”. 1–2 (55), s. 25–29, 2002. PMID: 12122940.
Dixon R., Gillotin C., Gibbens M., Posner J., Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. „British journal of clinical pharmacology”. 3 (43), s. 273–281, 1997. PMID: 9088582.
Cittadini E., May A., Straube A., Evers S., Bussone G., Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. „Archives of neurology”. 11 (63), s. 1537–1542, 2006. DOI: 10.1001/archneur.63.11.nct60002. PMID: 16966497.
Pascual J., Navarro A., Caminero AB., Jurado C. Experience with intranasal zolmitriptan in cluster headache. „Neurología (Barcelona, Spain)”. 3 (21), s. 131–134, 2006. PMID: 16575626.
Logemann CD., Rankin LM. Newer intranasal migraine medications. „American family physician”. 1 (61), s. 180–186, 2000. PMID: 10643958.

pubmedcentral.nih.gov

Kayser V., Aubel B., Hamon M., Bourgoin S. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. „British journal of pharmacology”. 8 (137), s. 1287–1297, 2002. DOI: 10.1038/sj.bjp.0704979. PMID: 12466238.
Seaber E., On N., Dixon RM., Gibbens M., Leavens WJ., Liptrot J., Chittick G., Posner J., Rolan PE., Pack RW. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). „British journal of clinical pharmacology”. 6 (43), s. 579–587, 1997. PMID: 9205817.

scbt.com (Global: low place; Polish: 4,755^th place)

datasheets.scbt.com

Zolmitriptan SC-220415. Santa Cruz Biotechnology. [dostęp 2019-11-17]. (ang.).

sigmaaldrich.com (Global: 774^th place; Polish: 132^nd place)

Zolmitryptan [PDF], karta charakterystyki produktu Sigma-Aldrich, Merck, numer katalogowy: SML0248 [dostęp 2019-11-17] .

Zolmitryptan (Polish Wikipedia)

aafp.org (Global: 2,559th place; Polish: 3,830th place)

ama-assn.org (Global: 4,430th place; Polish: low place)

archneur.ama-assn.org

arsxxi.com (Global: low place; Polish: low place)

doi.org (Global: 2nd place; Polish: 5th place)

drugbank.ca (Global: 5,595th place; Polish: 359th place)

go.drugbank.ca

mp.pl (Global: low place; Polish: 285th place)

nih.gov (Global: 5th place; Polish: 7th place)

ncbi.nlm.nih.gov

pubmedcentral.nih.gov

scbt.com (Global: low place; Polish: 4,755th place)

datasheets.scbt.com

sigmaaldrich.com (Global: 774th place; Polish: 132nd place)

aafp.org (Global: 2,559^th place; Polish: 3,830^th place)

ama-assn.org (Global: 4,430^th place; Polish: low place)

doi.org (Global: 2^nd place; Polish: 5^th place)

drugbank.ca (Global: 5,595^th place; Polish: 359^th place)

mp.pl (Global: low place; Polish: 285^th place)

nih.gov (Global: 5^th place; Polish: 7^th place)

scbt.com (Global: low place; Polish: 4,755^th place)

sigmaaldrich.com (Global: 774^th place; Polish: 132^nd place)